Autologous Cell Therapy
Autologous Cell Therapy involves extracting one’s cells, manipulating them and returning them to one’s body. It has several advantages compared to allogeneic cell therapy, including immediate donor availability and no HLA matching required, which significantly reduces the risks to the patient.
Esco VacciXcell offers various solutions that simplify autologous cell therapy processing using bone marrow and adipose-derived mesenchymal stem cells. The CradlePro-Iso is a cell processing system, includes the CelCradle™ bioreactor system, Esco’s CO2 incubator, Esco’s Versati™ centrifuge, and Esco’s Orbicult Shaker; this one-stop system fully encloses the entire autologous cell therapy process in a cGMP isolator. Due to the CelCradle™ system’s high productivity, a single CelCradle™ bottle can produce an adequate number of mesenchymal stem cells (up to 1 billion) for 1 patient.
The CradlePro-Iso is ideal for hospitals or when working with a few patients per run. Esco VacciXcell also offers cell processing centers to cater to a larger number of patients for autologous cell therapy.
CAR T-Cell Therapy
Aside from bone marrow derived and adipose-derived mesenchymal stem cells, Esco VacciXcell also provides solutions for CAR-T Cell Therapy.
Chimeric Antigen Receptor or CAR T Cells normally start out as T Cells. T cells play a key role in cell-mediated immunity and can mediate long-lived, antigen specific, effector and immune memory responses. Although T cells get rid of harmful substances, there is one thing that they cannot eradicate and that is cancer. Using gene transfer technologies, T cells can be genetically modified to express antibody binding domains. This approach may be applied to chimeric antigen receptors or CARs.
T cells are collected by drawing out blood from the diagnosed patient and then removing other blood components such as plasma, platelets or white blood cells. The T cells are sent out to a laboratory or drug manufacturing facility where they are genetically engineered.
T cells collected from the patient will be proliferated. Scientists will inject T cells with a virus that turns the normal T cells into CAR T cells. The lentivirus is commonly used for this therapy due to its capability to transduce both dividing and non-dividing cells.
Genetically engineered T cells produces CARs on their surface. This allows the T cells to recognize an antigen on targeted tumor cells. CAR T cells will then be proliferated under controlled conditions until there is enough quantity to start the therapy. CAR T cells will be introduced to the patient's body through infusion.
Esco VacciXcell offers cell processing isolators and cell processing centers, which are comprised of all the necessary tools and apparatus for CAR T-Cell proliferation. These isolators and centers are also easily customizable to suit the facilities’ equipment and capacity requirements.